IPP Bureau
PM urges vaccine manufacturers to scale production capacity
By IPP Bureau - April 21, 2021
The country has constantly worked with the spirit of public-private partnership
Pharma and medical device to play a pivotal role: Gowda
By IPP Bureau - April 21, 2021
The Department of Pharmaceuticals launched the PLI scheme for promoting domestic manufacturing of bulk drugs, with a financial outlay of Rs. 6,940 crore across 53 APIs over 6 years
Vaishali Pharma initiates 30 products registration
By IPP Bureau - April 19, 2021
The company also plans to register the similar range of products in the neighbouring countries.
Covaxin vaccine production to increase 7x by August 2021
By IPP Bureau - April 18, 2021
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
Lonza and Immunitas announce manufacturing agreement
By IPP Bureau - April 18, 2021
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
Glenmark Life Sciences files for IPO
By IPP Bureau - April 18, 2021
The IPO comprises a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals
Aceto acquires specialty exipients company A&C
By IPP Bureau - April 16, 2021
Acquisition of A&C expands Aceto’s Western manufacturing footprint
IMPCL revenue crosses Rs. 160 crore
By IPP Bureau - April 15, 2021
Presently, IMPCL is manufacturing 656 classical Ayurvedic, 332 Unani and 71 proprietary Ayurvedic medicines for the various diseases spectrum
Merck publishes sustainability report for 2020
By IPP Bureau - April 13, 2021
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
NATCO receives approval for Ibrutinib tablets from ANDA
By IPP Bureau - April 11, 2021
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
Aurore to merge with Solara in an all-stock transaction
By IPP Bureau - April 10, 2021
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
Hester to commercialize vaccines for animals
By IPP Bureau - April 09, 2021
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
Zydus Cadila announces USFDA approval for Ibrutinib capsules
By IPP Bureau - April 08, 2021
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
Dr. Reddy's Laboratories launches Sapropterin Dihydrochloride powder for oral solution in US
By IPP Bureau - April 08, 2021
Sapropterin dihydrochloride powder for oral solution is available in 100 mg unit dose
Panacea to produce 100 mn doses of Sputnik V vaccine
By IPP Bureau - April 06, 2021
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
